Two Drug Approvals in Two Years...Michael Metzger, CEO, Syndax Pharmaceuticals
In time for the 2026 ASCO Annual Meeting in Chicago, we're highlighting 3 BioTech companies shaping the future of cancer treatment...
On this episode of BioTech Nation: how Syndax Pharmaceuticals got two new drugs approved in the last two years, for the treatment of acute myeloid leukemia and graft vs. host disease in both adults and children. CEO Michael Metzger talks to Moira about Syndax's approach to getting the drugs across the finish line, and how they've now set their sights on additional indications and cancer therapies.
